Generate Biomedicines, Inc. GENB
12.57 USD -0.92 (-6.82%)
At closeNov 12, 2026, 4:00 PM EST
12.57 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
11.50 Day range 13.33
11.00 52-week range 22.67
- YTD
- -0.63%
- 1 year
- -0.63%
News
benzinga.com Generate Biomedicines Q3 EPS $(0.68) Misses $(0.59) Estimate, Sales $4.220M Miss $7.750M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.59) by 15.25 percent. This is a 65.48 percent increase over…
globenewswire.com Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand…
benzinga.com Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market Generate Biomedicines & Zealand Pharma team up to develop AI-engineered protein therapies for obesity & metabolic diseases.
benzinga.com Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of…- benzinga.com HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
benzinga.com Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trialsFirst patient treated in new clinical…- benzinga.com HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.
benzinga.com Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.- benzinga.com HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…- benzinga.com Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of…
benzinga.com Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
benzinga.com Why Constellation Brands Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and raising its FY27 guidance. Other gainers include DXF, EHGO, JEM, TC, VMAR, LGPS, BTOG, LUNR, and BE.…- benzinga.com Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22 Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.
benzinga.com HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $16 to $25.- benzinga.com Generate Biomedicines Q1 EPS $(1.07) Misses $(0.54) Estimate, Sales $7.224M Beat $5.938M Estimate Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.54) by 98.15 percent. This is a 33.95 percent increase over…
benzinga.com This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades, downgrades, initiations. See opinions on CRDO.
benzinga.com HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.
benzinga.com Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26 Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.- benzinga.com Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20 Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $20.
- benzinga.com Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24 Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.
benzinga.com Cantor Fitzgerald Initiates Coverage On Generate Biomedicines with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating.
benzinga.com This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. KBH, SOLV, SDHC, GENB coverage initiated.- benzinga.com Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30 Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.
benzinga.com Preview: Generate Biomedicines, Inc Set To IPO Tomorrow